|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001721,
umls-concept:C0003618,
umls-concept:C0004927,
umls-concept:C0015127,
umls-concept:C0028833,
umls-concept:C0032897,
umls-concept:C0043100,
umls-concept:C0086045,
umls-concept:C0087111,
umls-concept:C0547047,
umls-concept:C0681850,
umls-concept:C0911014,
umls-concept:C1314792,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-9-22
|
|
pubmed:abstractText |
Ghrelin is secreted primarily by the stomach and circulates as both acylated and desacyl ghrelin. Acylated (but not desacyl) ghrelin stimulates appetite. Both concentrations are elevated in Prader-Willi syndrome (PWS), suggesting that ghrelin may contribute to hyperphagia and overweight in these subjects. We evaluated whether long-acting octreotide (Oct) decreases acylated and desacyl ghrelin concentrations, body mass, appetite and compulsive behaviour towards food in adolescents with PWS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1479-683X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
159
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
381-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18603572-Adolescent,
pubmed-meshheading:18603572-Appetite,
pubmed-meshheading:18603572-Blood Glucose,
pubmed-meshheading:18603572-Body Composition,
pubmed-meshheading:18603572-Body Height,
pubmed-meshheading:18603572-Body Mass Index,
pubmed-meshheading:18603572-Body Weight,
pubmed-meshheading:18603572-Child,
pubmed-meshheading:18603572-Cross-Over Studies,
pubmed-meshheading:18603572-Feeding Behavior,
pubmed-meshheading:18603572-Female,
pubmed-meshheading:18603572-Gallbladder Diseases,
pubmed-meshheading:18603572-Gastrointestinal Agents,
pubmed-meshheading:18603572-Ghrelin,
pubmed-meshheading:18603572-Homeostasis,
pubmed-meshheading:18603572-Humans,
pubmed-meshheading:18603572-Insulin-Like Growth Factor I,
pubmed-meshheading:18603572-Male,
pubmed-meshheading:18603572-Octreotide,
pubmed-meshheading:18603572-Peptide YY,
pubmed-meshheading:18603572-Prader-Willi Syndrome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
|
|
pubmed:affiliation |
Endocrinology and Diabetes Unit, British Columbia's Children's Hospital, University of British Columbia, 4480 Oak Street, Vancouver, Canada.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
